Kamada to Announce Q4 Earnings on March 11
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy KMDA?
Source: seekingalpha
- Earnings Announcement: Kamada is set to release its Q4 earnings on March 11 before market open, with a consensus EPS estimate of $0.08, reflecting a 14.3% year-over-year increase, indicating ongoing improvements in profitability that may attract investor interest.
- Revenue Expectations: Analysts forecast Kamada's Q4 revenue to reach $46.62 million, representing a 19.5% year-over-year growth, which underscores the company's strong performance in market demand and product sales, potentially laying the groundwork for future expansion.
- Historical Performance: Over the past two years, Kamada has beaten EPS estimates 63% of the time and revenue estimates 63% of the time, suggesting a consistent ability to exceed market expectations, which may bolster confidence in its future performance.
- Future Outlook: Kamada anticipates achieving double-digit profitable growth by 2026, a projection that not only reflects the company's confidence in future market opportunities but also may attract long-term investors, further driving stock price appreciation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KMDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KMDA
Wall Street analysts forecast KMDA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.980
Low
13.00
Averages
14.00
High
15.00
Current: 8.980
Low
13.00
Averages
14.00
High
15.00
About KMDA
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kamada to Announce Q4 Earnings on March 11
- Earnings Announcement: Kamada is set to release its Q4 earnings on March 11 before market open, with a consensus EPS estimate of $0.08, reflecting a 14.3% year-over-year increase, indicating ongoing improvements in profitability that may attract investor interest.
- Revenue Expectations: Analysts forecast Kamada's Q4 revenue to reach $46.62 million, representing a 19.5% year-over-year growth, which underscores the company's strong performance in market demand and product sales, potentially laying the groundwork for future expansion.
- Historical Performance: Over the past two years, Kamada has beaten EPS estimates 63% of the time and revenue estimates 63% of the time, suggesting a consistent ability to exceed market expectations, which may bolster confidence in its future performance.
- Future Outlook: Kamada anticipates achieving double-digit profitable growth by 2026, a projection that not only reflects the company's confidence in future market opportunities but also may attract long-term investors, further driving stock price appreciation.
See More
Analyst Predicts Increase in Hubspot Stock, Along with Insights on McGraw Hill, UHS, and Other Stocks.
Report Overview: Recent reports from investment and research firms provide insights into analysts' perspectives on various companies.
Disclaimer: The views expressed in these reports do not reflect the opinions or recommendations of Barron’s.
Investment Services: Some report issuers may have existing or potential investment-banking relationships with the companies analyzed.
Purpose of Reports: The reports serve as a sampling of analyst thinking rather than definitive investment advice.
See More
Kamada Forecasts $200M-$205M Revenue for 2026 with 13% Growth
- 2026 Financial Outlook: Kamada projects revenues of $200 million to $205 million for 2026, representing a 13% year-over-year increase based on the midpoint of 2025 guidance, highlighting the company's ongoing organic growth potential across its diverse product portfolio in the biopharmaceutical sector.
- Adjusted EBITDA Growth: The company anticipates adjusted EBITDA to reach $50 million to $53 million in 2026, reflecting a 23% increase from the midpoint of 2025, which signifies a substantial enhancement in profitability and boosts investor confidence.
- Strong Cash Position: Kamada expects to end 2025 with approximately $75 million in cash, ensuring financial flexibility for future investments and business expansions, thereby strengthening its competitive edge in global markets.
- Strategic Development Focus: The company will continue to prioritize new business development and M&A transactions to accelerate long-term profitable growth, a strategy that will enrich its marketed product portfolio and generate synergies with existing operations.
See More
Kamada Secures Supply Tender Extension, Ensuring $5-$7 Million Annual Sales
- Contract Extension: Kamada has been awarded an extension of its existing supply tender from Canadian Blood Services for four specialty plasma-derived products, ensuring annual sales of approximately $5-$7 million between Q2-26 and Q1-28, thereby securing its market position in Canada.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA of $40 million to $44 million, reflecting strong and consistent performance in the market.
- Growth Outlook: Kamada projects double-digit growth in revenues and profitability in 2026, driven by its robust commercial portfolio and expansion of its biosimilar offerings, indicating strong competitive positioning in future markets.
- Strategic Development: The company intends to pursue additional contracts in key strategic territories, leveraging its strong cash position and existing commercial infrastructure to drive long-term growth and enhance its international market presence.
See More
Kamada Secures Supply Tender Extension from CBS, Ensuring $5-$7 Million Annual Sales
- Contract Extension: Kamada has secured an extension of its existing supply tender from Canadian Blood Services, ensuring annual sales of approximately $5-$7 million between Q2-26 and Q1-28, thereby reinforcing its leadership position in the Canadian market.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, reflecting strong confidence in future performance.
- Growth Outlook: Kamada projects double-digit growth in revenues and profitability in 2026, driven by a robust commercial portfolio and expansion of its biosimilar offerings, indicating significant commercial potential in international markets.
- Strategic Development: The company plans to enhance revenue growth through the expansion of normal source plasma sales and collection operations, showcasing its long-term growth strategy in the biopharmaceutical sector.
See More
Kamada Halts Phase 3 Trial for Genetic Disorder, Reaffirms Future Projections
Trial Discontinuation: Kamada Ltd. has announced the discontinuation of its Phase 3 InnovAATe trial for Inhaled AAT aimed at treating Alpha-1 Antitrypsin Deficiency (AATD) due to low likelihood of demonstrating significant efficacy in improving lung function.
Stock Impact: Following the announcement, Kamada's stock experienced a decline of 5.51%, reflecting bearish market sentiment.
Future Outlook: Despite the trial setback, Kamada's CEO expressed confidence in the company's growth prospects, reiterating revenue guidance for 2025 and projecting double-digit growth in revenues and profitability for 2026.
Business Development Focus: Kamada plans to leverage its strong cash position to pursue new business development opportunities while continuing to expand its commercial portfolio, which includes FDA-approved products and a growing biosimilar portfolio.
See More
Kamada to Announce Q4 Earnings on March 11
- Earnings Announcement: Kamada is set to release its Q4 earnings on March 11 before market open, with a consensus EPS estimate of $0.08, reflecting a 14.3% year-over-year increase, indicating ongoing improvements in profitability that may attract investor interest.
- Revenue Expectations: Analysts forecast Kamada's Q4 revenue to reach $46.62 million, representing a 19.5% year-over-year growth, which underscores the company's strong performance in market demand and product sales, potentially laying the groundwork for future expansion.
- Historical Performance: Over the past two years, Kamada has beaten EPS estimates 63% of the time and revenue estimates 63% of the time, suggesting a consistent ability to exceed market expectations, which may bolster confidence in its future performance.
- Future Outlook: Kamada anticipates achieving double-digit profitable growth by 2026, a projection that not only reflects the company's confidence in future market opportunities but also may attract long-term investors, further driving stock price appreciation.
See More
Analyst Predicts Increase in Hubspot Stock, Along with Insights on McGraw Hill, UHS, and Other Stocks.
Report Overview: Recent reports from investment and research firms provide insights into analysts' perspectives on various companies.
Disclaimer: The views expressed in these reports do not reflect the opinions or recommendations of Barron’s.
Investment Services: Some report issuers may have existing or potential investment-banking relationships with the companies analyzed.
Purpose of Reports: The reports serve as a sampling of analyst thinking rather than definitive investment advice.
See More
Kamada Forecasts $200M-$205M Revenue for 2026 with 13% Growth
- 2026 Financial Outlook: Kamada projects revenues of $200 million to $205 million for 2026, representing a 13% year-over-year increase based on the midpoint of 2025 guidance, highlighting the company's ongoing organic growth potential across its diverse product portfolio in the biopharmaceutical sector.
- Adjusted EBITDA Growth: The company anticipates adjusted EBITDA to reach $50 million to $53 million in 2026, reflecting a 23% increase from the midpoint of 2025, which signifies a substantial enhancement in profitability and boosts investor confidence.
- Strong Cash Position: Kamada expects to end 2025 with approximately $75 million in cash, ensuring financial flexibility for future investments and business expansions, thereby strengthening its competitive edge in global markets.
- Strategic Development Focus: The company will continue to prioritize new business development and M&A transactions to accelerate long-term profitable growth, a strategy that will enrich its marketed product portfolio and generate synergies with existing operations.
See More
Kamada Secures Supply Tender Extension, Ensuring $5-$7 Million Annual Sales
- Contract Extension: Kamada has been awarded an extension of its existing supply tender from Canadian Blood Services for four specialty plasma-derived products, ensuring annual sales of approximately $5-$7 million between Q2-26 and Q1-28, thereby securing its market position in Canada.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA of $40 million to $44 million, reflecting strong and consistent performance in the market.
- Growth Outlook: Kamada projects double-digit growth in revenues and profitability in 2026, driven by its robust commercial portfolio and expansion of its biosimilar offerings, indicating strong competitive positioning in future markets.
- Strategic Development: The company intends to pursue additional contracts in key strategic territories, leveraging its strong cash position and existing commercial infrastructure to drive long-term growth and enhance its international market presence.
See More
Kamada Secures Supply Tender Extension from CBS, Ensuring $5-$7 Million Annual Sales
- Contract Extension: Kamada has secured an extension of its existing supply tender from Canadian Blood Services, ensuring annual sales of approximately $5-$7 million between Q2-26 and Q1-28, thereby reinforcing its leadership position in the Canadian market.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, reflecting strong confidence in future performance.
- Growth Outlook: Kamada projects double-digit growth in revenues and profitability in 2026, driven by a robust commercial portfolio and expansion of its biosimilar offerings, indicating significant commercial potential in international markets.
- Strategic Development: The company plans to enhance revenue growth through the expansion of normal source plasma sales and collection operations, showcasing its long-term growth strategy in the biopharmaceutical sector.
See More
Kamada Halts Phase 3 Trial for Genetic Disorder, Reaffirms Future Projections
Trial Discontinuation: Kamada Ltd. has announced the discontinuation of its Phase 3 InnovAATe trial for Inhaled AAT aimed at treating Alpha-1 Antitrypsin Deficiency (AATD) due to low likelihood of demonstrating significant efficacy in improving lung function.
Stock Impact: Following the announcement, Kamada's stock experienced a decline of 5.51%, reflecting bearish market sentiment.
Future Outlook: Despite the trial setback, Kamada's CEO expressed confidence in the company's growth prospects, reiterating revenue guidance for 2025 and projecting double-digit growth in revenues and profitability for 2026.
Business Development Focus: Kamada plans to leverage its strong cash position to pursue new business development opportunities while continuing to expand its commercial portfolio, which includes FDA-approved products and a growing biosimilar portfolio.
See More
